Amgen Stock - Sunday background on the biotech heavyweight
21.06.2026 - 14:23:57 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 14:23 CET. Details in the imprint.
Amgen (US0311621009) is one of the largest biotech companies in the Standard & Poor's 500 index, known for blockbuster biologic therapies. With no new company-specific filings or ad-hoc releases this weekend, the Sunday focus turns to background, history and management structure at the group.
Background and data on Amgen stock
Key figures, regulatory filings and company announcements for Amgen stock are available in the dedicated topic area and on the group’s investor relations pages.
How Amgen became a biotech leader
Amgen traces its roots to 1980 in Thousand Oaks, California, when it was founded as Applied Molecular Genetics, focusing early on recombinant DNA technology and biologics. Over the decades it evolved from a research-focused start-up into a diversified global biotech group.
Early landmark products such as erythropoietin analogs for anemia and granulocyte colony-stimulating factors for neutropenia established Amgen’s commercial base and funded broader research. These therapies helped move the company from niche biotech status into the ranks of major pharmaceutical players.
Corporate structure and management
Amgen today operates globally with a centralized headquarters in Thousand Oaks and additional key facilities in the United States and Europe. The company is organized around therapeutic areas and functional units, including research and development, manufacturing, and commercial operations.
The board of directors oversees corporate governance, while an executive leadership team runs day-to-day operations; these structures reflect standard US large-cap governance practices in the healthcare sector, with committees dedicated to audit, compensation and compliance.
The product behind the stock
Amgen generates revenue primarily from innovative biologic medicines and biosimilars across oncology, inflammation, bone health and cardiovascular disease. The company’s model centers on discovering, developing, manufacturing and marketing these prescription therapies worldwide through its own sales infrastructure and selected partnerships.
Where the stock trades today
Amgen shares trade on Nasdaq in US dollars; the latest available quote and market capitalization can be obtained from the main exchange and financial data providers.
Key facts on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
